Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1345-1350

  Ayude, Daniel ^a,b   Gacio, Gloria ^a   De La Cadena, María Páez ^a   Pallas, Estrella ^c   Martínez Zorzano, Vicenta Soledad ^a   De Carlos, Alejandro ^a   Rodríguez Berrocal, Francisco Javier ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL XERAL CÍES   (Spain)

Author keywords

CYFRA 21 1; Diagnosis; HNSCC; SCC; Serum; Sialic acid; L fucosidase

Indexed keywords

ALPHA LEVO FUCOSIDASE; ANTIGEN CYFRA21.1; CARCINOEMBRYONIC ANTIGEN; KERATIN; N ACETYLNEURAMINIC ACID; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; CASE CONTROL STUDY; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; METABOLISM; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

ALPHA-L-FUCOSIDASE; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KERATINS; MALE; N-ACETYLNEURAMINIC ACID; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 2142860216     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1345     Document Type: Article

References (31)

1. Tannapfel A and Weber A: Tumor markers in squamous cell carcinoma of the head and neck: clinical effectiveness and prognostic value. Eur Arch Otorhinolaryngol 258: 83-88, 2001. (Pubitemid 32186484)
2. Mevio E, Benazzo M, Galioto P, Spriano P and Pizzala R: Use of serum markers in the diagnosis and management of laryngeal cancer. Clin Otolaryngol 16: 90-92, 1991.
3. Dreyfuss AI, Clark JR and Andersen JW: Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembrionic antigen and lactic dehydrogenase as tumor markers in squamous cell carcinoma of the head and neck. Cancer 70: 2499-2503, 1992.
4. Walther EK, Dahlmann N and Gorgulla HT: Tumour markers in the diagnosis and follow-up of head and neck cancer: role of CEA, CA 19-9, SCC, TK, and dTTPase. Head Neck 15: 230-235, 1993. (Pubitemid 23122105)
5. Rassekh CH, Johnson JT and Eibling DE: Circulating markers in squamous cell carcinoma of the head and neck: a review. Eur J Cancer Oral Oncol 30B: 23-28, 1994. (Pubitemid 24055770)
6. Laarman DA, van Kamp GJ, Balm AJ, Braakhuis BJ and Snow GB: Carcinoembryonic antigen and head and neck cancer. Clin Otolaryngol 16: 182-186, 1991.
7. Straka MB, Wagner RL, Johnson JT, Kachman KK and Eibling DE: The lack of utility of a tumor marker panel in head and neck carcinoma. Squamous cell carcinoma antigen, carcino-embryonic antigen, lipid-associated sialic acid, and CA-125. Arch Otolaryngol Head Neck Surg 118: 802-805, 1992.
8. Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M and Gruener N: Cyfra 21-1: a new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryingol Head Neck Surg 121: 177-181, 1995.
9. Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P and Fateh-Moghadam A: CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res 16: 3117-3124, 1996. (Pubitemid 26390259)
10. Niemann AM, Coeroegh T, Gottschlich S, Lippert BM and Werner JA: Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Anticancer Res 17: 2859-2860, 1997. (Pubitemid 27434804)
11. Yen TC, Lin WY, Kao CH, Cheng KY and Wang S J: A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol 23: 82-86, 1998. (Pubitemid 28344944)
12. Ogawa T, Tsurusako Y, Kimura N, et al: Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Acta Otolaryngol 540 (Suppl): 72-76, 1999. (Pubitemid 29336477)
13. Lachowicz MA, Hassmann-Poznanska E, Kozlowski MD and Rzewnicki I: Squamous cell carcinoma antigen in patients with cancer of the larynx. Clin Otolaryngol 24: 270-273, 1999. (Pubitemid 29397094)
14. Greenman J, Homer JJ and Stafford ND: Markers in cancer of the larynx and pharynx. Clin Otolaryngol 25: 9-18, 2000. (Pubitemid 30137849)
15. Xing RD, Wang ZS, Li CQ, Tang QY, Jiang CB and Zhang YZ: Total sialic acid as a tumor marker for oral cancer. Int J Biol Marker 9: 239-242, 1994. (Pubitemid 24350345)
16. Van Hal NL, van Dongen GA, Ten Brink CB, Heider KH, Rech-Weichselbraun I, Snow GB and Brakenhoff RH: Evaluation of soluble CD44v6 as a potential serum marker of head and neck squamous cell carcinoma. Clin Cancer Res 5: 3534-3541, 1999.
17. Godin DA, Fitzpatric PC, Scandurro AB, Belafsky PC, Woodworth BA and Amedee RG: PH20: a novel tumor marker for laryngeal cancer. Arch Otolaryngol Head Neck Surg 126: 402-404, 2000. (Pubitemid 30140398)
18. Hermanek P and Sobin LH: UICC TNM classification of malignant tumours: head and neck tumours. 4th edition, 2nd revision. Springer, London, pp15-35, 1992.
19. Ayude D, Fernández-Rodríguez J, Rodríguez-Berrocal FJ, Martínez-Zorzano VS, de Carlos A, Gil E and Páez de la Cadena M: Value of the serum ́-L-fucosidase activity in the diagnosis of colorectal cancer. Oncology 59: 310-316, 2000.
20. Gornal AC, Bardwill CJ and David HM: Determination of serum proteins by means of Biuret reaction. J Biol Chem 177: 751-766, 1949.
21. American Society of Clinical Oncology: Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 14: 2843-2877, 1996.
22. Beck JR and Shultz EK: The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 110: 13-20, 1986. (Pubitemid 16011804)
23. Zweig MH and Campbell G: Receiver-operating characteristic (ROC) plots. A fundamental evaluation tool in clinical medicine. Clin Chem 39: 561-577, 1993. (Pubitemid 23118304)
24. Páez de la Cadena M, Fernández J, de Carlos A, Martínez-Zorzano VS, Gil-Martín E and Rodríguez-Berrocal FJ: Low levels of α-L-fucosidase activity in colorectal cancer are due to decreased amounts of the enzymatic protein and are related with Dukes' stage. Int J Oncol 9: 747-754, 1996.
25. Feijoo C, Páez de la Cadena M, Rodríguez-Berrocal FJ and Martínez-Zorzano VS: Sialic acid levels in serum and tissue from colorectal cancer patients. Cancer Lett 112: 155-160, 1997.
26. Erbil DM, Jones JD and Klee GG: Use and limitations of serum total and lipid-bound sialic acid concentrations as markers for colorectal cancer. Cancer 55: 404-409, 1985. (Pubitemid 15152814)
27. Plucinsky MC, Riley WM, Prorok JJ and Alhadeff JA: Total and lipid-associated serum sialic acid levels in cancer patients with different primary sites and differing degrees of metastatic involvement. Cancer 58: 2680-2685, 1986. (Pubitemid 17232928)
28. Verazin G, Riley WM, Gregory J, Tautu C, Prorok JJ and Alhadeff JA: Serum sialic acid and carcinoembrionic levels in the detection and monitoring of colorectal cancer. Dis Colon Rectum 33: 139-142, 1990. (Pubitemid 20063595)
29. Ropka ME, Goodwin WJ, Levine PA, Sasaki CT, Kirchner JC and Cantrell RW: Effective head and neck tumor markers. The continuing quest. Arch Otolaryngol Head Neck Surg 117: 1011-1014, 1991.
30. Goumas PD, Mastronikolis NS, Mastorakou AN, Vassilakos PJ and Nikiforidis GC: Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 59: 106-114, 1997. (Pubitemid 27197366)
31. Crook MA, Scott DA, Stapleton JA, Palmer RM, Wilson RF and Sutherland G: Circulating concentrations of C-reactive protein and total sialic acid in tobacco smokers remain unchanged following one year of validated smoking cessation. Eur J Clin Invest 30: 861-865, 2000.